Advances in the Development of Antituberculotics Acting on Multidrug-Resistant Strains
Department of Inorganic and Organic Chemistry, Faculty of Pharmacy, Charles University, Hradec Králové
The aim of this review is to outline the recent advances in the development of new drugs against multidrug-resistant tuberculosis (MDR-TB). The occurrence of resistance to anti-tuberculosis drugs, particularly of MDR-TB, has become a major public health problem. The emergence of MDR-TB has made many currently available anti-TB drugs ineffective. Due to a many reasons, there is an urgent need to identify new drug targets and to find novel chemical structures. The research of novel anti-MDR-TB potential drugs follows structure modification of known antituberculotics, new lead structures with novel mechanism of the action (linezolid, TMC207, PA-824, OPC-67683, SQ109, FAS20013, LL-3858, BM212) and novel drug targets, i.e. cell wall biosynthesis (mycolic acid synthesis, protein synthesis, arabinogalactan and peptidoglycan biosynthesis inhibitors) or other novel targets.
Full text (PDF)